Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Principal Financial Officer | March 18, 2026 | March 19, 2026 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | Principle Financial Officer | February 07, 2019 | February 11, 2019 |
| KINETA, INC./DEPTI · Entity 77778 | Interim Head of Finance | May 12, 2020 | May 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date March 18, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,500 |
Reported balance
After 2026-03-18 transaction · row 1
1 source rowRow 1 · 2026-03-18 · Purchase · Acquired 5,000 · Balance 7,500 |
GENOCEA BIOSCIENCES, INC.
Report date February 07, 2019 · Filed February 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2029-02-07 | Direct | 75,000 |
Reported balance
After 2019-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-07 · Grant · Acquired 75,000 · Balance 75,000 F1: The Stock Option will vest as to 1/4th of the shares subject to the option on the first anniversary of the Grant Date and thereafter as to 1/36th of the shares on each subsequent monthly anniversary of February 7, 2020 (rounded down to the nearest whole share, except for the final vesting period, with respect to which all remaining shares will vest). |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest as to 1/4th of the shares subject to the option on the first anniversary of the Grant Date and thereafter as to 1/36th of the shares on each subsequent monthly anniversary of February 7, 2020 (rounded down to the nearest whole share, except for the final vesting period, with respect to which all remaining shares will vest).
KINETA, INC./DE
Report date May 12, 2020 · Filed May 15, 2020
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 19, 2026 21:29 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 5,000 | $1.42 | $7,100.00 |
DisclosureSEC source: 0001193125-26-116247 · ownership.xml · nonDerivative · entry 1 Alfieri Michael · CIK 0001744687 · Principal Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:09 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 2,500 | $5.30 | $13,250.00 |
DisclosureSEC source: 0000950170-25-109391 · ownership.xml · nonDerivative · entry 1 Alfieri Michael · CIK 0001744687 · Principal Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 20:59 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001457612-19-000014 · wf-form4_154993675242348.xml · derivative · entry 1 Alfieri Michael · CIK 0001744687 · Principle Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: The Stock Option will vest as to 1/4th of the shares subject to the option on the first anniversary of the Grant Date and thereafter as to 1/36th of the shares on each subsequent monthly anniversary of February 7, 2020 (rounded down to the nearest whole share, except for the final vesting period, with respect to which all remaining shares will vest). Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 17:13 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | PurchaseCommon Stock | 10,000 | $0.54 | $5,400.00 |
DisclosureSEC source: 0001457612-18-000082 · wf-form4_153695960601339.xml · nonDerivative · entry 1 Alfieri Michael · CIK 0001744687 · Principle Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.